Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases

Overview

Journal Int J Neuropsychopharmacol

Publisher Oxford University Press

Specialty Psychiatry

Date 2016 May 22

PMID 27207906

Citations 13

Authors

X Anton Alvarez

Irene Alvarez

Olalla Iglesias

Ignacio Crespo

Jesus Figueroa

Manuel Aleixandre

Carlos Linares

Elias Granizo

Manuel Garcia-Fantini

Jose Marey

Eliezer Masliah

Stefan Winter

Dafin Muresanu

Herbert Moessler

Affiliations

Soon will be listed here.

Abstract

Background: Low circulating brain derived neurotrophic factor may promote cognitive deterioration, but the effects of neurotrophic and combination drug therapies on serum brain derived neurotrophic factor were not previously investigated in Alzheimer's disease.

Methods: We evaluated the effects of Cerebrolysin, donepezil, and the combined therapy on brain derived neurotrophic factor serum levels at week 16 (end of Cerebrolysin treatment) and week 28 (endpoint) in mild-to-moderate Alzheimer's disease patients.

Results: Cerebrolysin, but not donepezil, increased serum brain derived neurotrophic factor at week 16, while the combination therapy enhanced it at both week 16 and study endpoint. Brain derived neurotrophic factor responses were significantly higher in the combination therapy group than in donepezil and Cerebrolysin groups at week 16 and week 28, respectively. Brain derived neurotrophic factor increases were greater in apolipoprotein E epsilon-4 allele carriers, and higher brain derived neurotrophic factor levels were associated with better cognitive improvements in apolipoprotein E epsilon-4 allele patients treated with Cerebrolysin and the combined therapy.

Conclusion: Our results indicate a synergistic action of Cerebrolysin and donepezil to increase serum brain derived neurotrophic factor and delaying cognitive decline, particularly in Alzheimer's disease cases with apolipoprotein E epsilon-4 allele.

Citing Articles

Cerebrolysin Induces Motor Recovery Along with Plastic Changes in Motoneurons and an Increase in GAP43 Protein in the Ventral Spinal Cord Following a Kainic Acid Excitotoxic Lesion in the Rat Motor Cortex.

Martinez-Torres N, Cardenas-Bedoya J, Torres-Mendoza B Neurochem Res. 2024; 50(1):31.

PMID: 39580783 DOI: 10.1007/s11064-024-04288-5.

Neuroprotective effects of cerebroprotein hydrolysate and its combination with antioxidants against oxidative stress-induced HT22 cell death.

Yang E, Kim J, Na D Toxicol Res. 2024; 40(4):541-550.

PMID: 39345752 PMC: 11436692. DOI: 10.1007/s43188-024-00248-x.

Neurotrophins in the Neuropathophysiology, Course, and Complications of Obstructive Sleep Apnea-A Narrative Review.

Gabryelska A, Turkiewicz S, Ditmer M, Sochal M Int J Mol Sci. 2023; 24(3).

PMID: 36768132 PMC: 9916304. DOI: 10.3390/ijms24031808.

The effect of combination pretreatment of donepezil and environmental enrichment on memory deficits in amyloid-beta-induced Alzheimer-like rat model.

Gholami J, Negah S, Rajabian A, Saburi E, Hajali V Biochem Biophys Rep. 2022; 32:101392.

PMID: 36438603 PMC: 9694055. DOI: 10.1016/j.bbrep.2022.101392.

Modulation of Amyloid-β and Tau in Alzheimer's Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil.

Alvarez X, Winston C, Barlow J, Sarsoza F, Alvarez I, Aleixandre M J Alzheimers Dis. 2022; 90(2):705-717.

PMID: 36155516 PMC: 9697063. DOI: 10.3233/JAD-220575.

References

Leyhe T, Eschweiler G, Stransky E, Gasser T, Annas P, Basun H . Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis. 2009; 16(3):649-56. DOI: 10.3233/JAD-2009-1004. View

Alvarez X, Sampedro C, Cacabelos R, Linares C, Aleixandre M, Garcia-Fantini M . Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin. Int J Neuropsychopharmacol. 2009; 12(7):867-72. DOI: 10.1017/S1461145709990101. View

Lee J, Shin B, You Y, Kim J, Yoon S, Jeon D . Decreased serum brain-derived neurotrophic factor levels in elderly korean with dementia. Psychiatry Investig. 2010; 6(4):299-305. PMC: 2808800. DOI: 10.4306/pi.2009.6.4.299. View

Coelho F, Vital T, Miki Stein A, Arantes F, Rueda A, Camarini R . Acute aerobic exercise increases brain-derived neurotrophic factor levels in elderly with Alzheimer's disease. J Alzheimers Dis. 2013; 39(2):401-8. DOI: 10.3233/JAD-131073. View

Nascimento C, Pereira J, de Andrade L, Garuffi M, Talib L, Forlenza O . Physical exercise in MCI elderly promotes reduction of pro-inflammatory cytokines and improvements on cognition and BDNF peripheral levels. Curr Alzheimer Res. 2014; 11(8):799-805. DOI: 10.2174/156720501108140910122849. View

Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A . Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease. Stem Cell Res. 2015; 15(1):54-67. DOI: 10.1016/j.scr.2015.04.008. View

Hartwig K, Fackler V, Jaksch-Bogensperger H, Winter S, Furtner T, Couillard-Despres S . Cerebrolysin protects PC12 cells from CoCl2-induced hypoxia employing GSK3β signaling. Int J Dev Neurosci. 2014; 38:52-8. DOI: 10.1016/j.ijdevneu.2014.07.005. View

Weinstein G, Beiser A, Choi S, Preis S, Chen T, Vorgas D . Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study. JAMA Neurol. 2013; 71(1):55-61. PMC: 4056186. DOI: 10.1001/jamaneurol.2013.4781. View

Diniz B, Reynolds 3rd C, Begley A, Dew M, Anderson S, Lotrich F . Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: a longitudinal study. J Psychiatr Res. 2013; 49:96-101. PMC: 3921964. DOI: 10.1016/j.jpsychires.2013.11.004. View

10.

Leyhe T, Stransky E, Eschweiler G, Buchkremer G, Laske C . Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2007; 258(2):124-8. DOI: 10.1007/s00406-007-0764-9. View

11.

Klein A, Williamson R, Santini M, Clemmensen C, Ettrup A, Rios M . Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2010; 14(3):347-53. DOI: 10.1017/S1461145710000738. View

12.

Alvarez A, Aleixandre M, Linares C, Masliah E, Moessler H . Apathy and APOE4 are associated with reduced BDNF levels in Alzheimer's disease. J Alzheimers Dis. 2014; 42(4):1347-55. PMC: 4931817. DOI: 10.3233/JAD-140849. View

13.

Schmidt H, Duman R . Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology. 2010; 35(12):2378-91. PMC: 2955759. DOI: 10.1038/npp.2010.114. View

14.

Ahmed H, Salem A, Atta H, Ghazy M, Aglan H . Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson's disease in rat model?. Hum Exp Toxicol. 2014; 33(12):1217-31. DOI: 10.1177/0960327114524238. View

15.

Alvarez X, Cacabelos R, Sampedro C, Couceiro V, Aleixandre M, Vargas M . Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr Alzheimer Res. 2011; 8(5):583-91. DOI: 10.2174/156720511796391863. View

16.

Ubhi K, Rockenstein E, Vazquez-Roque R, Mante M, Inglis C, Patrick C . Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease. J Neurosci Res. 2012; 91(2):167-77. DOI: 10.1002/jnr.23142. View

17.

Honea R, Cruchaga C, Perea R, Saykin A, Burns J, Weinberger D . Characterizing the role of brain derived neurotrophic factor genetic variation in Alzheimer's disease neurodegeneration. PLoS One. 2013; 8(9):e76001. PMC: 3784423. DOI: 10.1371/journal.pone.0076001. View

18.

Georgy G, Nassar N, Mansour H, Abdallah D . Cerebrolysin Ameloriates Cognitive Deficits in Type III Diabetic Rats. PLoS One. 2013; 8(6):e64847. PMC: 3686810. DOI: 10.1371/journal.pone.0064847. View

19.

Chen M, Russo-Neustadt A . Running exercise- and antidepressant-induced increases in growth and survival-associated signaling molecules are IGF-dependent. Growth Factors. 2007; 25(2):118-31. DOI: 10.1080/08977190701602329. View

20.

Gauthier S, Proano J, Jia J, Froelich L, Vester J, Doppler E . Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015; 39(5-6):332-47. DOI: 10.1159/000377672. View